2021
Influence of immunomodulatory drugs on the gut microbiota
Cohen I, Ruff WE, Longbrake EE. Influence of immunomodulatory drugs on the gut microbiota. Translational Research 2021, 233: 144-161. PMID: 33515779, PMCID: PMC8184576, DOI: 10.1016/j.trsl.2021.01.009.Peer-Reviewed Original ResearchMeSH KeywordsAdaptive ImmunityCell ProliferationCytokinesFemaleGastrointestinal MicrobiomeHost Microbial InteractionsHumansImmune Checkpoint InhibitorsImmunity, InnateImmunity, MucosalImmunologic FactorsImmunomodulationLymphocytesMaleModels, ImmunologicalSex FactorsTranslational Research, BiomedicalConceptsImmune checkpoint inhibitorsGut microbiotaCheckpoint inhibitorsAutoimmune diseasesMainstay of treatmentType of immunotherapyInflammatory cytokine inhibitorComprehensive literature searchMechanism of actionImmunomodulatory medicationsDrug-induced shiftImmunomodulatory drugsCytokine inhibitorsImmunotherapy effectImmune cellsClinical significanceImmune responseMost immunotherapiesCommensal microbesDrug efficacyImmunotherapyLiterature searchAntiproliferative drugsMedicationsMicrobiota
2019
Siponimod Chips Away at Progressive MS
Longbrake EE, Hafler DA. Siponimod Chips Away at Progressive MS. Cell 2019, 179: 1440. PMID: 31951523, PMCID: PMC8023412, DOI: 10.1016/j.cell.2019.11.034.Peer-Reviewed Original ResearchConceptsProgressive multiple sclerosisGadolinium-enhancing MRI lesionsInflammatory disease activityImmunomodulatory medicationsDisability progressionDisease activityMRI lesionsProgressive MSNeurologic disabilityPMS patientsMultiple sclerosisSiponimodMedicationsSclerosisPatientsLesionsBedsideProgression